Stryker Corporation (SYK) recently announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.This reflects a strategic move to streamline Stryker’s portfolio by divesting its U.S. spinal implants business, enabling the company to focus on higher-growth areas. Additionally, the planned sale of related international operations sign ...

Stryker Corporation (SYK) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $4.01, which beat the Zacks Consensus Estimate of $3.87 by 3.6%. The bottom line also improved 15.9% year over year. Our model estimate for the metric was $3.85 billion.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS was $1.41, down 52.7% from the year-ago quarter’s level. The significant decline was due to recording of a goodwill and impairment charge related to SYK’s Spine business. ...

2025年1月28日，骨科巨头 史赛克 Stryker 宣布，已达成协议将其 美国脊柱植入物业务 出售给投资公司 Viscogliosi Brothers ，新公司命名为 VB Spine # 史赛克的战略调整 史赛克出售脊柱植入业务是其战略调整的一部分， 此次交易预计将于2025年上半年完成。 在交易最终完成之前，史赛克的美国脊柱植入物业务和VB Spine将独立运营。 交易完成后， VB Spine将作为史赛克的战略合作伙伴，将获得独家使用权，使用Mako脊柱系统和辅助的Copilot系统，用于VB Spine在脊柱手术中的植入 物。 此外，该最终协议还包含一项具有法律约束力的要约， 计划收购史赛克在法国的脊柱植入物业务 ，但前提是必须与员工及/或员工代表进行必要的协商。预 计史赛克在其他国际市场的脊柱植入物业务也将被出售，前提是满足所有法律和监管要求，包括进行任何必要的协商。 此次合作预计将使史赛克和VB Spine都能更好地满足客户及其患者的需求，实现更快的增长，并为所有利益相关者创造更大的价值。 # 史赛克的脊柱业务 史赛克的脊柱植入物业务主要集中在脊柱疾病的治疗和手术解决方案上。 1. 产品范围： ...

Stryker Corporation (NYSE:SYK) Q4 2024 Earnings Conference Call January 28, 2025 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Andy Pierce - Group President of MedSurg & Neurotechnology Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Pito Chickering - Deutsch ...

Core Viewpoint - Stryker Corporation is set to discuss its Q4 2024 earnings, highlighting key financial metrics and future outlook during the conference call [1][2]. Group 1: Company Participants - The conference call will feature key executives including Kevin Lobo (Chairman, CEO & President), Andy Pierce (Group President of MedSurg & Neurotechnology), and Glenn Boehnlein (CFO) [1]. - Other participants from various financial institutions will also be present to engage in the Q&A session [1]. Group 2: Conference Call Logistics - The call is scheduled for January 28, 2025, at 4:30 PM ET and will be recorded for replay purposes [2]. - The operator has indicated that the call may extend until no later than 6 PM EST due to the amount of content to be covered [2]. Group 3: Forward-Looking Statements - The discussions will include forward-looking statements, with potential factors affecting actual results outlined in recent SEC filings [3]. - Non-GAAP financial measures will also be discussed, with reconciliations to GAAP measures available in the press release [3].

For the quarter ended December 2024, Stryker (SYK) reported revenue of $6.44 billion, up 10.7% over the same period last year. EPS came in at $4.01, compared to $3.46 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $6.35 billion, representing a surprise of +1.34%. The company delivered an EPS surprise of +3.62%, with the consensus EPS estimate being $3.87.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expe ...

Stryker (SYK) came out with quarterly earnings of $4.01 per share, beating the Zacks Consensus Estimate of $3.87 per share. This compares to earnings of $3.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.62%. A quarter ago, it was expected that this medical device maker would post earnings of $2.78 per share when it actually produced earnings of $2.87, delivering a surprise of 3.24%.Over the last four quarters, the compan ...

Exhibit 99.1 STRYKER REPORTS 2024 OPERATING RESULTS AND 2025 OUTLOOK MedSurg and Neurotechnology net sales of $3.9 billion and $13.5 billion increased 10.6% in the quarter, 11.1% in constant currency, and increased 11.1% in the full year, 11.6% in constant currency. Organic net sales increased 10.1% and 11.2% in the quarter and full year including 8.5% and 9.5% from increased unit volume and 1.6% and 1.7% from higher prices. Portage, Michigan - January 28, 2025 - Stryker (NYSE:SYK) reported operating result ...

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% to $6.4 billionOrganic net sales increased 10.2%Reported operating income margin of 9.0%Adjusted operating income margin(1) increased 200 bps to 29.2%Reported EPS decreased 52.7% to $1.41Adjusted EPS(1) increased 15.9% to $4.01 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Cons ...

Core Insights - Stryker has entered into a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, forming a new entity called VB Spine, LLC [1][2] - The transaction aims to enhance the focus and growth potential of the spinal implants business as an independent company [2][3] - VB Spine will have exclusive access to Stryker's Mako Spine and Copilot technologies for its spinal procedures, fostering a strategic partnership [2][3] Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually with innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [5] - Viscogliosi Brothers is a family-owned investment firm focused on the neuro-musculoskeletal industry, having founded and grown 42 businesses across more than 80 countries since its establishment in 1999 [6] - Barings, LLC is a financial partner in this transaction, managing over $421 billion in assets as of December 31, 2024 [7] Transaction Details - The sale includes a binding offer to acquire Stryker's spinal implants business in France, pending employee consultations and regulatory requirements [3] - The transaction is expected to close in the first half of 2025, with both Stryker and VB Spine continuing to operate separately until then [3]